NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) include mogamulizumab (POTELIGEO®) as a preferred treatment option in certain patients1
For use in stages:
- IB-IIA MF
- IIB MF—Limited tumor disease
- IIB MF—Generalized tumor disease
- III MF—Erythrodermic disease
- IVA1 SS
- IVA2 SS
For use in stages:
- IVA2—Non-Sézary
- IVB—Visceral/solid organ disease
NCCN Guidelines® goals of therapy for Mycosis Fungoides and Sézary Syndrome should be individualized but often include:
- Minimizing risk of disease progression
- Attaining symptom control
- Minimizing risk of adverse effects
- Absence of cumulative toxicity
Other NCCN Guidelines Treatment Considerations
Most treatments do not result in durable remissions off of treatment. Other than allogeneic HCT, therapies are not given with curative intent.
Generally, skin-directed therapies and systemic therapy regimens that can be tolerated for longer durations with lower rates of cumulative toxicity, less immunosuppression, and/or higher efficacy are used in earlier lines of therapy.
Therapies with lower side-effect profiles and an absence of cumulative toxicity are often given in an ongoing or maintenance fashion to improve and maintain disease control and quality of life.
- aNCCN recommends systemic therapies in combination with skin-directed therapies in select cases. There is limited safety data for the use of TSEBT in combination with mogamulizumab.
- NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
- HCT=hematopoietic stem cell transplant; NCCN=National Comprehensive Cancer Network; TSEBT=total skin electron beam therapy
Continue exploring why POTELIGEO is a preferred treatment option
Explore POTELIGEO- Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Primary Cutaneous Lymphomas V.1.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed July 13, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org.